According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Several other equities research analysts have also commented on the stock. ValuEngine raised shares of Sartorius from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. DZ Bank reaffirmed a “sell” rating on shares of Sartorius in a research report on Tuesday, April 2nd.
Sartorius (OTCMKTS:SARTF) last posted its earnings results on Tuesday, February 19th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.84 by ($0.02). The company had revenue of $470.78 million for the quarter, compared to the consensus estimate of $478.80 million. Sartorius had a net margin of 9.36% and a return on equity of 18.37%. As a group, analysts expect that Sartorius will post 3.31 EPS for the current year.
There is no company description available for Sartorius AG.
Featured Article: What is the return on assets formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.